Figure 1. Increased GLUT1 expression and glucose uptake in NSCLC cells treated with gefitinib.

The indicated non-small-cell lung cancer (NSCLC) cells cultured in the absence (Control) and presence of 10 μM gefitinib for 3 days were subjected to glucose uptake assay (A) and immunoblot analysis of GLUT1 expression (B). Values in the graphs represent means + SD from three independent experiments. ^*P < 0.05.